Highlights Immatics N.V.

Equities

IMTX

NL0015285941

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
13.44 ^USD	+8.21%		+16.36%	+27.64%

May. 15	Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating	MT
May. 14	Immatics' Q1 Loss Narrows. Revenue Rises	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immatics' Q1 Loss Narrows. Revenue Rises	May. 14	MT
Immatics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Sector Update: Health Care Stocks Gain Pre-Bell Thursday	Mar. 21	MT
Sector Update: Health Care	Mar. 21	MT
Immatics Swings to 2023 Net Loss, Revenue Falls -- Shares Down Pre-Bell	Mar. 21	MT
Immatics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Immatics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Immatics N.V. Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRame in an Ongoing Phase 1 Trial	Nov. 08	CI
Immatics N.V. Receives FDA Regenerative Medicine Advanced Therapy Designation for ACTengine(R) IMA203 TCR-T Monotherapy	23-10-24	CI
Moderna, Immatics to Collaborate to Develop Novel Cancer Therapies	23-09-11	MT
Moderna, Inc. and Immatics N.V. Announces Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics	23-09-11	CI
Immatics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Immatics N.V. Initiates Phase 1/2 Clinical Trial to Evaluate Promame TCR Bispecific IMA402 in Patients with Advanced Solid Tumors	23-08-10	CI
Immatics Receives $35 Million Investment From Bristol-Myers Squib	23-07-24	MT
Bristol Myers Squibb Invests $35 Million in Immatics	23-07-24	DJ
Immatics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
Immatics N.V. Announces First Bristol Myers Squibb Opt-In of TCR-T Candidate from Ongoing Multi-Target Strategic Collaboration	23-05-02	CI
Bristol Myers Squibb Enters into Exclusive Worldwide License Agreement with Immatics N.V	23-05-01	CI
Immatics Swings to Profit in 2022, Revenue Increases	23-03-21	MT
Immatics Posts Narrower Q3 Loss, Revenue Increases	22-11-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immatics N.V.

Equities

IMTX

NL0015285941

Highlights

Filters